PUBLISHER: DelveInsight | PRODUCT CODE: 1226533
PUBLISHER: DelveInsight | PRODUCT CODE: 1226533
"ASN002 (Gusacitinib) Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ASN002 (Gusacitinib) for Hand Eczema (HE) in the 7MM. A detailed picture of the ASN002 (Gusacitinib) for Hand Eczema in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the ASN002 (Gusacitinib) for Hand Eczema. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ASN002 (Gusacitinib) market forecast, analysis for Hand Eczema in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Hand Eczema.
ASN002 is an oral, potent, dual Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK) inhibitor. Both JAK and SYK kinases are involved in both cytokine production and signaling and have been implicated in the pathogenesis of various types of lymphomas, solid tumors, myeloproliferative and inflammation disorders.
Mechanism of Action
Autoimmune, inflammatory, and immunological-based diseases have complex pathogeneses that involve interactions between multiple cytokines and immune cells. JAK kinases play a significant role in these inflammatory conditions. The JAK kinases family (JAK1, JAK2, JAK3 and TYK2) is involved in signaling pathways of the Th2, Th22, Th1 and Th17 cytokines involved in AD pathogenesis. Hence, JAK kinases play a significant role in inflammatory conditions, particularly those driven by cytokines. SYK is a vital mediator of immunoreceptor signaling in macrophages, neutrophils, mast cells, and B cells. SYK mediated signaling leads to the increased release of inflammatory cytokines, lipid mediators, and various proteases. Activated B cells and macrophages also act as antigen-presenting cells and potent activators of T cells in inflammatory conditions. SYK also plays a critical role in IL-17R signaling in keratinocytes and in keratinocyte proliferation and terminal differentiation.
Gusacitinib simultaneously targets multiple disease-relevant signaling pathways to allow for greater control over those pathways that drive disease pathogenesis. SYK-JAK inhibition with gusacitinib modulates Th1, Th2, Th22, and Th17 cytokines, thereby targeting both the immune cells and epithelial cells responsible for the disease pathogenesis of CHE. This multi-pathway approach holds the potential to treat a wide range of dermatological diseases.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ASN002 (Gusacitinib) Analytical Perspective by DelveInsight
This report provides a detailed market assessment of ASN002 (Gusacitinib) in Hand Eczema (HE) in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.
The report provides the clinical trials information of ASN002 (Gusacitinib) in Hand Eczema (HE) covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions